ClinicalTrials.gg
RecruitingNCT05956106Updated Nov 3, 2023

Effect of Mulberry Fruit Powder in Metabolic Syndrome

An interventional study of Black Mulberry Fruit Powder in Metabolic Syndrome, sponsored by University of Veterinary and Animal Sciences, Lahore - Pakistan. Recruiting at 1 site in Pakistan. Open to participants aged 35 Years to 50 Years. Per ClinicalTrials.gov, last updated 2023-11-03.

Sponsored by University of Veterinary and Animal Sciences, Lahore - Pakistan · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 11 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
35 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Metabolic Syndrome with a site in Pakistan — 6 open to participants now, 7 under way, none of them phase 3. Metabolic Syndrome · Pakistan.

Planned enrollment
13th of 16
40 · median 60
Started
2023
with 2 others
No phase
14 of 16
6 open now
Registered
6th of 16
by date
Lead sponsor
4 of 16
University of Veterinary and Animal Sciences, Lahore - Pakistan

Among the 16 studies in Metabolic Syndrome with a site in Pakistan, this one is the 13th largest by planned enrollment, is one of 3 that started in 2023, is one of 14 with no phase, and was the 6th registered.

Metabolic Syndrome

2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

6 of the 16 studies in Metabolic Syndrome with a site in Pakistan are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.

This study: 35 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Metabolic Syndrome with a site in Pakistan, or all of them as a file.
02

Study summary

Metabolic syndrome is a raising concern globally, especially in developing countries such as Pakistan. To prevent its risk factors diet and lifestyle modification is major solution. Functional foods have additional benefits of treating disease while providing basic nutrients. Mulberry is a native fruit with the properties of functional food, it is rich in anthocyanin and different anti-obesity,anti-diabetic, and anti-hyperlipidemic treating potential antioxidants. Mulberry will prove its therapeutic potential against the risk factors of metabolic syndrome.

Read the detailed description

Metabolic syndrome, which is characterized by a number of concurrent risk factors. These risk factors include dysglycemia, high blood pressure, high triglyceride levels, low levels of HDL cholesterol, and obesity (particularly central adiposity). It is rapidly increasing the burden of non-communicable diseases (NCDs) in Pakistan. The prevalence of MetS in Pakistan is 28.6%, and suburban areas from the province of Punjab showed a high prevalence. Females are more prone to metabolic syndrome. Dietary and lifestyle modification can prevent MetS from converting into CVD, T2DM, and stroke. There is limited documented research in Pakistan related to the therapeutic roles of mulberry fruit powder. With respect to these limitations, the present study aims to assess the therapeutic roles of mulberry fruit powder consumption on metabolic syndrome.

The utilization of dried mulberry fruit powder (MFP) as a component of nutritional supplementation will effectively ameliorate the clinical markers associated with metabolic syndrome.

03

Conditions studied

  • Metabolic Syndrome

Keywords

  • Hypertension
  • Diabetes
  • Obesity
  • Hyperlipidemia
  • Mulberry
  • Anthocyanin
04

Who can participate

Ages eligible
35 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects having fasting total cholesterol level of ≥ 200 mg/dl or LDL cholesterol ≥ 130 mg/dl.
  • Fasting Blood Glucose ≥110mg/dl.
  • SBP ≥ 130/ ≥ 85 mmHg
  • Waist Circumference of ≥40 inches in males and ≥35 inches for females

Exclusion criteria

Exclusion Criteria:

  • Participants of age 55 or above
  • Participants who have less than two risk factors
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Metabolic syndrome patients

    Dried Mulberry fruit powder is used for preventing symptoms in Metabolic Syndrome patients Dietary intervention: Black Mulberry fruit powder Dosage: 45g per day

    Dietary Supplement: Black Mulberry Fruit Powder

Interventions

  • Dietary supplementBlack Mulberry Fruit Powder

    Anthocyanin plays a major role in preventing symptoms of metabolic syndrome.

    Also known as: Morus Nigra

06

What researchers measure

Primary outcomes

  1. Lipid profile will be assessed before and after the trial.

    The change in lipid profile, after consuming mulberry fruit powder for 45 days, will be assessed. The value will be closed to optimized values.

    Time frame: 45 days

  2. Fasting glucose level will be assessed before and after the trial

    The change in fasting glucose levels will be assessed after consuming mulberry fruit powder for 45 days.The values will be become close to optimized levels

    Time frame: 45 days

  3. Weight circumference will be measured before and after the trial

    The change in weight will be measured after consuming mulberry fruit powder for 45 days.The value will be close to normal range.

    Time frame: 45 days

  4. Blood pressure will be assessed before and after the trial.

    The change in systolic and diastolic blood pressure, after consuming mulberry fruit powder for 45 days. The values will become close to optimized levels.

    Time frame: 45 days

07

Study locations

1 of 1 sites recruiting
  • Shan Medicare Hospital
    Arifwala, Punjab 57450, Pakistan
    Recruiting
    • Dr. Muhammad Illyas, FCPS · Contact+923075055198
08

References and documents

Publications

  • Wan M, Li Q, Lei Q, Zhou D, Wang S. Polyphenols and Polysaccharides from Morus alba L. Fruit Attenuate High-Fat Diet-Induced Metabolic Syndrome Modifying the Gut Microbiota and Metabolite Profile. Foods. 2022 Jun 20;11(12):1818. doi: 10.3390/foods11121818. PubMed 35742014 ↗

Individual participant data

Plan to share: No — All available data will be confidential

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Dec 2023, 4 months after the start.

Of 627 non-industry interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 4 months is below that.

Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2023
First posted
Jul 21, 2023
StartActual
Aug 1, 2023
Primary completionEst.
Dec 1, 2023
CompletionEst.
Dec 1, 2023
Last update
Nov 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05956106
Lead sponsor
University of Veterinary and Animal Sciences, Lahore - Pakistan
Responsible party
Asif Ali (Lecturer, Department of Food Sciences and Human Nutrition, University of Veterinary and Animal Sciences, Lahore - Pakistan) — Principal investigator
First posted
Jul 21, 2023
Start date
Aug 1, 2023
Primary completion
Dec 1, 2023 (estimated)
Completion
Dec 1, 2023 (estimated)
Last update
Nov 3, 2023

Study contacts

Fiza Maqbool, DNS
Contact
fizach65@gmail.com
03008077414

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion